Announcements on Extended Partnerships and Results of Clinical Trials - Research Report on Allscripts, Edwards Lifesciences, Varian, OPKO, and Globus Medical Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 20, 2013 NEW YORK, June 20, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Edwards Lifesciences Corporation (NYSE: EW), Varian Medical Systems, Inc. (NYSE: VAR), OPKO Health, Inc. (NYSE: OPK), and Globus Medical, Inc. (NYSE: GMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Allscripts Healthcare Solutions,Inc. Research Report On June 13, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that OnePartner Health Information Exchange (HIE) has extended its partnership with the Company, adding the dbMotion platform to support HIE's growth. Acquired by Allscripts in March 2013, dbMotion's capabilities will enhance the ability of healthcare providers who participate in HIE to communicate with one another to manage population health and enhance patient care. Further, the partnership will help in a smooth transition for providers as the industry moves from fee-for-service to fee-for-value. "Allscripts solutions are enhancing multiple aspects of electronic connectivity in healthcare," said Paul M. Black, President and CEO of Allscripts. The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1d85_MDRX] -- Edwards Lifesciences Corporation Research Report On June 17, 2013, Edwards Lifesciences Corporation (Edwards Lifesciences) announced unprecedented long-term durability results for bovine pericardial heart valves. The results are based on a study of the Carpentier-Edwards PERIMOUNT aortic valve in a subset of patients aged 60 years or younger at the time of operation. The study tracked patients for an almost 25-year period and determined that expected valve durability for the patients was greater than 17 years. "Pericardial valve use has increased over time. These long-term data on the PERIMOUNT valve strengthen the evidence for surgeons to utilize Edwards' pericardial tissue valves, including in selected patients of age 60 and under," said Prof. Michel Aupart, M.D., Head of the Department of Cardiovascular and Thoracic Surgery, University Hospital of Tours, France, and a consultant to Edwards Lifesciences. The Full Research Report on Edwards Lifesciences Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4fbc_EW] -- Varian Medical Systems,Inc. Research Report On June 13, 2013, Varian Medical Systems, Inc. (Varian) announced that clinicians at The Ohio State University are now using Varian software to plan and manage radiotherapy treatments delivered on a Siemens medical linear accelerator. The Companies developed and deployed an interface that connects Varian's ARIA oncology information system with Siemens' ONCOR and PRIMUS accelerators and imaging systems. Siemens received 510(k) clearance in March 2013 from the US Food and Drug Administration (FDA) for connectivity between Varian's ARIA software and Siemens' ONCOR and PRIMUS linear accelerators. Further, Varian also launched a special service and support program to support oncology treatment centers converting to ARIA from other third-party oncology information systems. The Full Research Report on Varian Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/b046_VAR] -- OPKO Health,Inc. Research Report On May 23, 2013, OPKO Health, Inc. (OPKO) reported that the Company has surpassed 50% enrollment in the first Phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD), and vitamin D insufficiency. The first trial is part of two identical randomized, double-blind, placebo-controlled, multi-side studies, which are designed to establish the safety and efficacy of Rayaldy as a new treatment for SHPT in the targeted population. "Rayaldy is being developed as a much needed and safer alternative to currently used activated vitamin D hormones," said Dr. David Bushinsky, Chief of Nephrology at the University of Rochester. Joel Z. Melnick, M.D., Vice President of Clinical Research and Development at OPKO's Renal Division, added, "Most CKD patients have insufficient stores of vitamin D due to the abnormal upregulation of CYP24, an enzyme which specifically destroys vitamin D and its metabolites. Many recent studies in CKD patients have demonstrated that over-the-counter and presently available prescription vitamin D supplements cannot reliably raise blood vitamin D prohormone levels or effectively treat SHPT. In contrast, our phase 2b trial has demonstrated that Rayaldy effectively and safely treats both SHPT and the underlying vitamin D insufficiency." The Full Research Report on OPKO Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/cb42_OPK] -- Globus Medical,Inc. Research Report On June 17, 2013, Globus Medical, Inc. (Globus) announced jury verdict in a patent infringement case in a US District Court brought by DePuy Synthes Products, LLC (Synthes). Globus stated that a formal judgment has not yet been entered in the case and there are a number of motions and hearings to be resolved; however, the jury found that prior versions of three products previously sold by Globus did infringe on Synthes' patents and awarded monetary damages of $16 million. Globus does not expect this verdict to impact its business or future revenues, as the said three products are no longer part of the Company's product portfolio. Further, the Company does not expect the verdict to impair Globus' ability to sell any of its current products and will not require it to make any royalty payments to Synthes based on current or future sales. However, the Company plans to overturn the verdict in post-trial motions as it believes that the facts and the law do not support the jury's findings of infringement and patent validity. The Full Research Report on Globus Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5f95_GMED] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Announcements on Extended Partnerships and Results of Clinical Trials - Research Report on Allscripts, Edwards Lifesciences,
Press spacebar to pause and continue. Press esc to stop.